Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
AR and SMAD4	androgen receptor	SMAD family member 4	Generic Transcription Pathway Nuclear Receptor transcription pathway	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by BMP Transcriptional regulation of pluripotent stem cells Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and BRCA1	androgen receptor	breast cancer 1, early onset	Generic Transcription Pathway Nuclear Receptor transcription pathway	ATM mediated phosphorylation of repair proteins Meiotic recombination Fanconi Anemia pathway ATM mediated response to DNA double-strand break Homologous Recombination Repair Meiotic synapsis Homologous recombination repair of replication-independent double-strand breaks Recruitment of repair and signaling proteins to double-strand breaks Double-Strand Break Repair	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and CCNE1	androgen receptor	cyclin E1	Generic Transcription Pathway Nuclear Receptor transcription pathway	E2F mediated regulation of DNA replication DNA Damage/Telomere Stress Induced Senescence Cellular Senescence Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes p53-Dependent G1/S DNA damage checkpoint G0 and Early G1 S Phase Cyclin E associated events during G1/S transition Cell Cycle, Mitotic p53-Dependent G1 DNA Damage Response SCF(Skp2)-mediated degradation of p27/p21 G1/S Transition G1/S-Specific Transcription Cell Cycle Checkpoints Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Mitotic G1-G1/S phases G1/S DNA Damage Checkpoints	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and EGFR	androgen receptor	epidermal growth factor receptor	Generic Transcription Pathway Nuclear Receptor transcription pathway	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
AR and CTNNB1	androgen receptor	catenin (cadherin-associated protein), beta 1, 88kDa	Generic Transcription Pathway Nuclear Receptor transcription pathway	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide	Urea
AR and MDM2	androgen receptor	MDM2 proto-oncogene, E3 ubiquitin protein ligase	Generic Transcription Pathway Nuclear Receptor transcription pathway	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade Stabilization of p53 Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Transmission across Chemical Synapses PIP3 activates AKT signaling Oncogene Induced Senescence p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Signalling by NGF Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Trafficking of AMPA receptors Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR Oxidative Stress Induced Senescence Cell Cycle Checkpoints Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide	Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
AR and CCND1	androgen receptor	cyclin D1	Generic Transcription Pathway Nuclear Receptor transcription pathway	Chromatin organization Signaling by NOTCH Ubiquitin-dependent degradation of Cyclin D G1 Phase S Phase Cell Cycle, Mitotic RMTs methylate histone arginines Ubiquitin-dependent degradation of Cyclin D1 Cyclin D associated events in G1 Chromatin modifying enzymes Pre-NOTCH Transcription and Translation Pre-NOTCH Expression and Processing Mitotic G1-G1/S phases	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide	Arsenic trioxide
ATP6V1A and CDKN1A	ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Phagosomal maturation (early endosomal stage) Iron uptake and transport Latent infection of Homo sapiens with Mycobacterium tuberculosis Transferrin endocytosis and recycling Insulin receptor recycling Signaling by Insulin receptor	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
BAD and CDKN1A	BCL2-associated agonist of cell death	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling Activation of BH3-only proteins Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Programmed Cell Death Innate Immune System Intrinsic Pathway for Apoptosis Signaling by PDGF DAP12 interactions Signalling by NGF GAB1 signalosome Cell death signalling via NRAGE, NRIF and NADE Signaling by Ligand-Responsive EGFR Variants in Cancer p75 NTR receptor-mediated signalling NGF signalling via TRKA from the plasma membrane BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR NRAGE signals death through JNK Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
CCND1 and CDKN1B	cyclin D1	cyclin-dependent kinase inhibitor 1B (p27, Kip1)	Chromatin organization Signaling by NOTCH Ubiquitin-dependent degradation of Cyclin D G1 Phase S Phase Cell Cycle, Mitotic RMTs methylate histone arginines Ubiquitin-dependent degradation of Cyclin D1 Cyclin D associated events in G1 Chromatin modifying enzymes Pre-NOTCH Transcription and Translation Pre-NOTCH Expression and Processing Mitotic G1-G1/S phases	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 PI3K/AKT Signaling in Cancer Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints	Arsenic trioxide
CCND1 and CDKN2A	cyclin D1	cyclin-dependent kinase inhibitor 2A	Chromatin organization Signaling by NOTCH Ubiquitin-dependent degradation of Cyclin D G1 Phase S Phase Cell Cycle, Mitotic RMTs methylate histone arginines Ubiquitin-dependent degradation of Cyclin D1 Cyclin D associated events in G1 Chromatin modifying enzymes Pre-NOTCH Transcription and Translation Pre-NOTCH Expression and Processing Mitotic G1-G1/S phases	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence	Arsenic trioxide
CCND1 and BRCA1	cyclin D1	breast cancer 1, early onset	Chromatin organization Signaling by NOTCH Ubiquitin-dependent degradation of Cyclin D G1 Phase S Phase Cell Cycle, Mitotic RMTs methylate histone arginines Ubiquitin-dependent degradation of Cyclin D1 Cyclin D associated events in G1 Chromatin modifying enzymes Pre-NOTCH Transcription and Translation Pre-NOTCH Expression and Processing Mitotic G1-G1/S phases	ATM mediated phosphorylation of repair proteins Meiotic recombination Fanconi Anemia pathway ATM mediated response to DNA double-strand break Homologous Recombination Repair Meiotic synapsis Homologous recombination repair of replication-independent double-strand breaks Recruitment of repair and signaling proteins to double-strand breaks Double-Strand Break Repair	Arsenic trioxide
CCND1 and CTNNB1	cyclin D1	catenin (cadherin-associated protein), beta 1, 88kDa	Chromatin organization Signaling by NOTCH Ubiquitin-dependent degradation of Cyclin D G1 Phase S Phase Cell Cycle, Mitotic RMTs methylate histone arginines Ubiquitin-dependent degradation of Cyclin D1 Cyclin D associated events in G1 Chromatin modifying enzymes Pre-NOTCH Transcription and Translation Pre-NOTCH Expression and Processing Mitotic G1-G1/S phases	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Arsenic trioxide	Urea
BCL2 and MYC	B-cell CLL/lymphoma 2	v-myc avian myelocytomatosis viral oncogene homolog	Activation of BAD and translocation to mitochondria Inflammasomes The NLRP1 inflammasome Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways Programmed Cell Death Activation of BH3-only proteins BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Innate Immune System Intrinsic Pathway for Apoptosis	Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt Cyclin E associated events during G1/S transition binding of TCF/LEF:CTNNB1 to target gene promoters TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation G1/S Transition Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Mitotic G1-G1/S phases FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer S Phase Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT Signaling by NOTCH1 PEST Domain Mutants in Cancer Cyclin A:Cdk2-associated events at S phase entry Signaling by WNT in cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer	Ibuprofen Paclitaxel Docetaxel Rasagiline
BRCA1 and CTNNB1	breast cancer 1, early onset	catenin (cadherin-associated protein), beta 1, 88kDa	ATM mediated phosphorylation of repair proteins Meiotic recombination Fanconi Anemia pathway ATM mediated response to DNA double-strand break Homologous Recombination Repair Meiotic synapsis Homologous recombination repair of replication-independent double-strand breaks Recruitment of repair and signaling proteins to double-strand breaks Double-Strand Break Repair	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer		Urea
BRCA1 and SMAD2	breast cancer 1, early onset	SMAD family member 2	ATM mediated phosphorylation of repair proteins Meiotic recombination Fanconi Anemia pathway ATM mediated response to DNA double-strand break Homologous Recombination Repair Meiotic synapsis Homologous recombination repair of replication-independent double-strand breaks Recruitment of repair and signaling proteins to double-strand breaks Double-Strand Break Repair	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer
BRCA1 and SMAD4	breast cancer 1, early onset	SMAD family member 4	ATM mediated phosphorylation of repair proteins Meiotic recombination Fanconi Anemia pathway ATM mediated response to DNA double-strand break Homologous Recombination Repair Meiotic synapsis Homologous recombination repair of replication-independent double-strand breaks Recruitment of repair and signaling proteins to double-strand breaks Double-Strand Break Repair	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by BMP Transcriptional regulation of pluripotent stem cells Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer
BRCA2 and KAT2B	breast cancer 2, early onset	K(lysine) acetyltransferase 2B	Homologous DNA pairing and strand exchange Meiotic recombination Fanconi Anemia pathway Homologous Recombination Repair Homologous recombination repair of replication-independent double-strand breaks Double-Strand Break Repair Presynaptic phase of homologous DNA pairing and strand exchange	Signaling by NOTCH1 HD Domain Mutants in Cancer RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Clearance HATs acetylate histones Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway Pre-NOTCH Transcription and Translation Signaling by NOTCH1 Pre-NOTCH Expression and Processing Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Chromatin organization RNA Polymerase I Transcription Signaling by NOTCH Notch-HLH transcription pathway NOTCH1 Intracellular Domain Regulates Transcription Chromatin modifying enzymes Signaling by NOTCH1 PEST Domain Mutants in Cancer YAP1- and WWTR1 (TAZ)-stimulated gene expression Constitutive Signaling by NOTCH1 PEST Domain Mutants
BRCA2 and CHEK2	breast cancer 2, early onset	checkpoint kinase 2	Homologous DNA pairing and strand exchange Meiotic recombination Fanconi Anemia pathway Homologous Recombination Repair Homologous recombination repair of replication-independent double-strand breaks Double-Strand Break Repair Presynaptic phase of homologous DNA pairing and strand exchange
BRCA2 and H2AFX	breast cancer 2, early onset	H2A histone family, member X	Homologous DNA pairing and strand exchange Meiotic recombination Fanconi Anemia pathway Homologous Recombination Repair Homologous recombination repair of replication-independent double-strand breaks Double-Strand Break Repair Presynaptic phase of homologous DNA pairing and strand exchange	RNA Polymerase I Chain Elongation RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Mitotic Prophase Regulatory RNA pathways Deposition of new CENPA-containing nucleosomes at the centromere Cellular Senescence Signaling by Wnt Amyloids NoRC negatively regulates rRNA expression Packaging Of Telomere Ends RNF mutants show enhanced WNT signaling and proliferation Homologous recombination repair of replication-independent double-strand breaks ATM mediated phosphorylation of repair proteins DNA Damage/Telomere Stress Induced Senescence Chromosome Maintenance ATM mediated response to DNA double-strand break misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Chromatin organization formation of the beta-catenin:TCF transactivating complex Meiotic synapsis Senescence-Associated Secretory Phenotype (SASP) Chromatin modifying enzymes Recruitment of repair and signaling proteins to double-strand breaks SIRT1 negatively regulates rRNA Expression Condensation of Prophase Chromosomes MRN complex relocalizes to nuclear foci RNA Polymerase I Promoter Clearance Assembly of the RAD50-MRE11-NBS1 complex at DNA double-strand breaks M Phase Telomere Maintenance Nucleosome assembly XAV939 inhibits tankyrase, stabilizing AXIN Double-Strand Break Repair DNA methylation Transcriptional regulation by small RNAs Meiotic recombination RNA Polymerase I Transcription Epigenetic regulation of gene expression Negative epigenetic regulation of rRNA expression Cell Cycle, Mitotic PRC2 methylates histones and DNA RMTs methylate histone arginines TCF dependent signaling in response to WNT Oxidative Stress Induced Senescence Homologous Recombination Repair RNA Polymerase I Promoter Opening Signaling by WNT in cancer

Search Results for: Cancer